We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?
Read MoreHide Full Article
Key Takeaways
NeuroPace's Q2 revenues rose 17.1% to $22.8 million, while RNS System revenues climbed 21.3%.
NPCE trades at 4.44X forward sales versus 4.09X for its sub-industry and a 3.47X five-year median.
NeuroPace faces liquidity and IGE regulatory risks as it invests in commercial and technology expansion.
NeuroPace, Inc. (NPCE - Free Report) is showing better operating momentum as RNS System adoption expands and losses narrow. Second-quarter results supported the growth case, while a broader commercial reach and new technology tools could deepen utilization.
The hurdle is valuation. NPCE still trades above its medical-instruments peer benchmark and its own historical median, while profitability, liquidity and regulatory timing remain unresolved. That mix favors a more selective approach rather than chasing improving fundamentals.
NeuroPace’s Growth Is Improving Faster Than Profitability
Second-quarter 2026 revenues increased 17.1% year over year to $22.8 million. RNS System revenues rose 21.3% to $22.5 million, with active prescribers, accounts and the patient pipeline reaching record highs.
Adjusted operating loss narrowed to $2.8 million from $5 million a year earlier. Management also improved full-year adjusted EBITDA-loss guidance to $7.5-$8.5 million from $8.5-$9.5 million. The direction is favorable, but NeuroPace remains unprofitable and still needs revenue growth to translate into sustained cash generation.
Image Source: Zacks Investment Research
NPCE Trades at a Premium to Its Medical-Instruments Peers
NPCE trades at 4.44X forward 12-month sales per share versus 4.09X for the Zacks sub-industry. Its five-year median multiple is 3.47X, underscoring that investors are already paying above the stock’s longer-term norm.
That premium raises the execution bar. Faster RNS growth and narrowing losses support a better operating trajectory, but the valuation leaves less room for setbacks in adoption, regulatory progress or product development.
Image Source: Zacks Investment Research
NeuroPace Has Multiple Paths to Expand RNS Adoption
The company is extending its reach beyond Level 4 comprehensive epilepsy centers into community neurologists and Level 3 programs. These relationships can broaden patient identification and referrals while allowing some centers to diagnose, manage and treat patients directly when they have the needed infrastructure.
ECoG Assistant adds an AI-enabled workflow tool to the RNS platform, while remote care, automated detection and a next-generation system offer further avenues to improve clinician efficiency and patient access. LivaNova PLC (LIVN - Free Report) serves drug-resistant epilepsy through VNS Therapy. Medtronic plc (MDT - Free Report) offers deep brain stimulation for epilepsy. Those alternatives reinforce the importance of NeuroPace differentiating RNS through data, workflow and clinical utility.
NPCE Still Faces Execution and Liquidity Risks
NeuroPace ended the second quarter with $51.7 million in cash, cash equivalents and short-term investments versus $59 million in long-term borrowings. The company continues investing in commercial expansion, AI-enabled tools, regulatory programs and its next-generation platform.
Those investments could keep cash generation constrained if referral conversion or RNS adoption develops more slowly than expected. Regulatory uncertainty also remains around the idiopathic generalized epilepsy expansion after the FDA requested additional clinical information, making timing less predictable.
Image Source: Zacks Investment Research
NeuroPace’s Signals Favor Selective Patience
The operating picture is improving, but valuation and execution risk still argue against an aggressive stance. Investors may prefer to see more evidence that growth can support profitability and that regulatory pathways are becoming clearer before assigning more upside to the shares.
NPCE currently carries a Zacks Rank #3 (Hold) and a VGM Score of C. Its Growth Score of B and Momentum Score of B are favorable marks for growth characteristics and price momentum, respectively, while the Value Score of D reinforces the valuation concern. Together, those signals fit a balanced watch-and-wait posture rather than a clear buy case. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
View the Zacks #1 Rank List
Image: Shutterstock
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?
Key Takeaways
NeuroPace, Inc. (NPCE - Free Report) is showing better operating momentum as RNS System adoption expands and losses narrow. Second-quarter results supported the growth case, while a broader commercial reach and new technology tools could deepen utilization.
The hurdle is valuation. NPCE still trades above its medical-instruments peer benchmark and its own historical median, while profitability, liquidity and regulatory timing remain unresolved. That mix favors a more selective approach rather than chasing improving fundamentals.
NeuroPace’s Growth Is Improving Faster Than Profitability
Second-quarter 2026 revenues increased 17.1% year over year to $22.8 million. RNS System revenues rose 21.3% to $22.5 million, with active prescribers, accounts and the patient pipeline reaching record highs.
Adjusted operating loss narrowed to $2.8 million from $5 million a year earlier. Management also improved full-year adjusted EBITDA-loss guidance to $7.5-$8.5 million from $8.5-$9.5 million. The direction is favorable, but NeuroPace remains unprofitable and still needs revenue growth to translate into sustained cash generation.
Image Source: Zacks Investment Research
NPCE Trades at a Premium to Its Medical-Instruments Peers
NPCE trades at 4.44X forward 12-month sales per share versus 4.09X for the Zacks sub-industry. Its five-year median multiple is 3.47X, underscoring that investors are already paying above the stock’s longer-term norm.
That premium raises the execution bar. Faster RNS growth and narrowing losses support a better operating trajectory, but the valuation leaves less room for setbacks in adoption, regulatory progress or product development.
Image Source: Zacks Investment Research
NeuroPace Has Multiple Paths to Expand RNS Adoption
The company is extending its reach beyond Level 4 comprehensive epilepsy centers into community neurologists and Level 3 programs. These relationships can broaden patient identification and referrals while allowing some centers to diagnose, manage and treat patients directly when they have the needed infrastructure.
ECoG Assistant adds an AI-enabled workflow tool to the RNS platform, while remote care, automated detection and a next-generation system offer further avenues to improve clinician efficiency and patient access. LivaNova PLC (LIVN - Free Report) serves drug-resistant epilepsy through VNS Therapy. Medtronic plc (MDT - Free Report) offers deep brain stimulation for epilepsy. Those alternatives reinforce the importance of NeuroPace differentiating RNS through data, workflow and clinical utility.
NPCE Still Faces Execution and Liquidity Risks
NeuroPace ended the second quarter with $51.7 million in cash, cash equivalents and short-term investments versus $59 million in long-term borrowings. The company continues investing in commercial expansion, AI-enabled tools, regulatory programs and its next-generation platform.
Those investments could keep cash generation constrained if referral conversion or RNS adoption develops more slowly than expected. Regulatory uncertainty also remains around the idiopathic generalized epilepsy expansion after the FDA requested additional clinical information, making timing less predictable.
Image Source: Zacks Investment Research
NeuroPace’s Signals Favor Selective Patience
The operating picture is improving, but valuation and execution risk still argue against an aggressive stance. Investors may prefer to see more evidence that growth can support profitability and that regulatory pathways are becoming clearer before assigning more upside to the shares.
NPCE currently carries a Zacks Rank #3 (Hold) and a VGM Score of C. Its Growth Score of B and Momentum Score of B are favorable marks for growth characteristics and price momentum, respectively, while the Value Score of D reinforces the valuation concern. Together, those signals fit a balanced watch-and-wait posture rather than a clear buy case. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.